The Week

Revolution Medicines (RVMD) fell 2.98% this week to close at $203.77, underperforming the S&P 500 by about 2.18 percentage points (the S&P 500 was -0.8% this week). The week opened higher, reaching an intraday high of $213 on Tuesday 8 September, before pulling back. The stock closed at $207.32 on Tuesday and $207.68 on Wednesday, then slipped below $205 on Thursday to end at $203.35. On Friday it dipped to a low of $197.81 before recovering to close at $203.77. Weekly amplitude was 7.3%, with average daily volume of 1.45m shares — about 21% below the median pace for the past 60 sessions.

Key Events

There were no major company announcements or earnings this week. The narrative centred on RASONQUE (daraxonrasib): on Monday, commentary asked whether the first approval and NEJM data had shifted the investment story. On Tuesday, Veru announced that its oral sabizabulin showed potent preclinical activity in pancreatic cancer resistant to Revolution Medicines’ RASONQUE, and is advancing into a planned Phase 2 trial. On Friday, director Lorence H. Kim disclosed the sale of 17,090 common shares worth $3.57m. Overall, the week was driven by indirect discussion around the product rather than company-led news.

Analyst Ratings

Coverage stands at 21 analysts, with a consensus recommendation of strong buy. Sixteen rate it buy, four overweight, and one hold, with no underweight or sell ratings. The consensus target price is $251.21, about 23.28% above the latest price; the target range runs from $179 to $320, pointing to wide dispersion in views. Within a biotechnology universe of 506 names, RVMD ranks 21st in analyst ratings.

The Week Ahead

Macro data dominates the coming week: the New York Fed manufacturing index on Tuesday, followed on Wednesday by US retail sales, retail sales ex-autos, import prices, the NAHB housing market index, and EIA crude inventories. RVMD has no scheduled earnings, so the focus is on how high-multiple biotech names absorb macro liquidity signals, along with any fresh product data or regulatory developments.

In Short

RVMD pulled back slightly this week even as the sell-side view remains constructive: 21 analysts rate it strong buy, with a consensus target sitting 23% above spot, though the $179–$320 range underscores disagreement on valuation. Flow data from the latest session shows large-lot money as a net buyer, but overall turnover was light. The tension to watch is whether the high valuation holds up through a dense macro calendar, and whether external competitive signals around daraxonrasib intensify.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.